EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

EGFR and PI3K Signalling Pathways as Promising Targets on Circulating Tumour Cells from Patients with Metastatic Gastric Adenocarcinoma

Ann-Katrin Piper iD, Chelsea Penney, Jacqueline Holliday, Gary Tincknell iD, Yafeng Ma iD, Sarbar Napaki, Klaus Pantel iD, Daniel Brungs, Marie Ranson iD

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms25105565 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Ann-Katrin Piper und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia. Hauptthemen laut MEDLINE: Stomach Neoplasms, ErbB Receptors, Signal Transduction, Adenocarcinoma. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Tour de Cure.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The prognosis for metastatic gastric adenocarcinoma (mGAC) remains poor. Gene alterations in receptor tyrosine kinases (RTKs) such as epidermal growth factor receptor (EGFR) and their downstream effectors including catalytic subunit alpha of the phosphatidylinositol 3-kinase (PIK3CA) are common in mGAC. Targeted RTK and phosphatidylinositol-3-kinase (PI3K) treatments have demonstrated clinical benefits in other solid tumours and are key potential targets for clinical development against mGAC given the presence of recurrent alterations in these pathways. Furthermore, combination RTK/PI3K treatments may overcome compensatory mechanisms that arise using monotherapies, leading to improved patient outcomes. Herein, we investigated RTK/PI3K single and combination drug responses against our unique human mGAC-derived PIK3CA gain-of-function mutant, human epidermal growth factor receptor 2 (HER2)-negative, EGFR-expressing circulating tumour cell line, UWG02CTC, under two- and three-dimensional culture conditions to model different stages of metastasis. UWG02CTCs were highly responsive to the PI3K p110α-subunit targeted drugs PIK-75 (IC50 = 37.0 ± 11.1 nM) or alpelisib (7.05 ± 3.7 µM). Drug sensitivities were significantly increased in 3D conditions. Compensatory MAPK/ERK pathway upregulation by PI3K/Akt suppression was overcome by combination treatment with the EGFR inhibitor gefitinib, which was strongly synergistic. PIK-75 plus gefitinib significantly impaired UWG02CTC invasion in an organotypic assay. In conclusion, UWG02CTCs are a powerful ex vivo mGAC drug responsiveness model revealing EGFR/PI3K-targeted drugs as a promising combination treatment option for HER2-negative, RAS wild-type mGAC patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Stomach NeoplasmsErbB ReceptorsSignal TransductionAdenocarcinomaClass I Phosphatidylinositol 3-KinasesNeoplastic Cells, CirculatingHumansCell Line, TumorPhosphatidylinositol 3-KinasesNeoplasm MetastasisPhosphoinositide-3 Kinase InhibitorsProtein Kinase InhibitorsAntineoplastic AgentsThiazoles

Stichwörter der Autor:innen

3D cell cultureEGFRPI3K/AktPIK-75alpelisibc-Metcell signallingcirculating tumour cellsgastric cancergefitiniborganotypics

Substanzen

ErbB ReceptorsEGFR protein, humanClass I Phosphatidylinositol 3-KinasesPIK3CA protein, humanPhosphatidylinositol 3-KinasesAlpelisibPhosphoinositide-3 Kinase InhibitorsProtein Kinase InhibitorsAntineoplastic AgentsThiazoles

Autor:innen und Institutionen

  • School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia.
  • Molecular Horizons, University of Wollongong, Wollongong, NSW 2522, Australia.
  • Illawarra Cancer Care Centre, Wollongong Hospital, Wollongong, NSW 2500, Australia.
  • Centre for Circulating Tumour Cell Diagnostics & Research at the Ingham Institute for Applied Medical Research, South-Western Clinical School, University of New South Wales, Liverpool, NSW 2170, Australia.
  • Graduate School of Medicine, University of Wollongong, Wollongong, NSW 2522, Australia.
  • Department of Pathology, Wollongong Hospital, Wollongong, NSW 2500, Australia.

ORCID-Profile: Ann-Katrin Piper, Gary Tincknell, Yafeng Ma, Klaus Pantel, Marie Ranson

Förderung

  • Tour de Cure

Zitieren

APA

Piper, A. K., Penney, C., Holliday, J., Tincknell, G., Ma, Y., Napaki, S., Pantel, K., Brungs, D., & Ranson, M. (2024). EGFR and PI3K Signalling Pathways as Promising Targets on Circulating Tumour Cells from Patients with Metastatic Gastric Adenocarcinoma. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25105565

Vancouver

Piper AK, Penney C, Holliday J, Tincknell G, Ma Y, Napaki S, et al. EGFR and PI3K Signalling Pathways as Promising Targets on Circulating Tumour Cells from Patients with Metastatic Gastric Adenocarcinoma. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25105565

BibTeX
@article{Piper2024,
  author = {Piper, Ann-Katrin and Penney, Chelsea and Holliday, Jacqueline and Tincknell, Gary and Ma, Yafeng and Napaki, Sarbar and Pantel, Klaus and Brungs, Daniel and Ranson, Marie},
  title = {EGFR and PI3K Signalling Pathways as Promising Targets on Circulating Tumour Cells from Patients with Metastatic Gastric Adenocarcinoma},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms25105565}
}
Kostenlos starten →